Human Oncology & Pathogenesis Program
The Nikolaus Schultz Lab
The Schultz lab focuses on identifying the genomic alterations that underlie different types of cancer. By applying existing and novel computational methods to large scale cancer genomics data sets, the lab aims to better understand the complex mechanisms at the gene and at the pathway level that drive tumor initiation, progression and response to therapy, with the ultimate goal of identifying targeted therapeutic options for cancer patients. A new focus of the lab is the systematic extraction and standardization of clinical data elements from electronic health records. The lab is also involved in collaborative large-scale projects such as The Cancer Genome Atlas (TCGA), AACR Project GENIE, and the Human Tumor Atlas (HTAN). The group also has a strong interest in enabling discoveries by developing novel computational methods and databases that help bridge the divide between computer scientists on one side and clinicians and researchers on the other. Examples of these include the cBioPortal for Cancer Genomics, a popular resource for the visualization and analysis of cancer genomics data, and OncoKB, a precision oncology knowledgebase.
Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M; Cancer Genome Atlas Research Network, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018 Apr 5;173(2):321-337.e10. PMCID: PMC6070353.
Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, Ku GY, Riches JC, Tuvy Y, Kundra R, Bouvier N, Vakiani E, Gao J, Heins ZJ, Gross BE, Kelsen DP, Zhang L, Strong VE, Schattner M, Gerdes H, Coit DG, Bains M, Stadler ZK, Rusch VW, Jones DR, Molena D, Shia J, Robson ME, Capanu M, Middha S, Zehir A, Hyman DM, Scaltriti M, Ladanyi M, Rosen N, Ilson DH, Berger MF, Tang L, Taylor BS, Solit DB, Schultz N. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov. 2018 Jan;8(1):49-58. PMCID: PMC5813492.
Chakravarty D, Gao J, Phillips SM, Kundra R, et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol. 2017 Jul.
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov. 2012 May;2(5):401-4. PMCID: PMC3956037.
Nikolaus Schultz, PhD
Head of Knowledge Systems, Marie-Josée & Henry R. Kravis Center for Molecular Oncology
- Cancer biologist Nikolaus Schultz uses computational tools to study the diversity of genomic alterations underlying different cancer types.
- PhD, Freie Universitat Berlin
- Geoffrey Beene Junior Faculty Chair (2019)
- Josie Robertson Investigator (2013-2018)
- Stupski Prize in Prostate Cancer Computational Oncology (2015)
- Young Investigator Award, Prostate Cancer Foundation (2014)
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Nikolaus Schultz discloses the following relationships and financial interests:
Innovation in Cancer Informatics
Provision of Services (uncompensated)
TranSYS Personalized Medicine
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.